Skip to main content
OpenTrials
Completed

NCT Number: NCT05577156

SexoMBC2 Non Interventional Study

The study is composed of three paper self-questionnaires to be filled in by the patients included at distance (> 6 months) from their diagnosis of metastatic breast cancer, in order to limit the impact of the announcement on the filling out the questionnaires.

After verification of the eligibility criteria, the medical oncologist will present the study to patients coming to the ICL for a follow-up consultation as part of their regular care. The patients will meet with a clinical research nurse so that she can explain the again and answer any questions they may have. She will also give the patients the questionnaires questionnaires and will give a presentation of the questions asked. After this meeting, the patients will be given sufficient time to reflect on, which may extend until their next visit to the ICL, in order to express, if they wish, their opposition to participating in the study. If she agrees to participate, the patient can then complete the questionnaires as well as the complementary questionnaire and place them in a closed envelope to be given to the clinical research nurse. The completion of the questionnaires will be completely anonymous. The data of those who object to the use of their data will be deleted from the database.

After the completion of the questionnaires, and in order to allow a benefit for the patient, a semi-directive interview in the form of a teleconsultation with a psycho-oncologist and sexologist will be offered. The interviews are not mandatory.

The time to fill in the self-questionnaires is estimated at 30 minutes and the semi-directive interview can last up to one hour. Finally, at the end of the study, as part of her subsequent care, each patient participating in the study will have the possibility to renew a teleconsultation with the psycho-oncologist and sexologist if she feels the need. As the subject of the study may generate personal questions and lead to a request for psychological and/or sexological care.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Institut de Cancerologie de Lorraine

Vandœuvre-lès-Nancy, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Major woman
  • Patient with metastatic breast cancer, either initially or secondary metastatic breast cancer
  • RH+/HER2- tumor
  • Patient starting first line metastatic therapy or currently undergoing 1st line metastatic treatment
  • Patient diagnosed with metastatic breast cancer 6 months or more
  • WHO 1 or 2 patient
  • Postmenopausal or not
  • Patient able to understand the French language

Exclusion criteria

  • Patient WHO>2
  • Patient undergoing chemotherapy
  • HER2+ or triple negative tumor
  • Male
  • Patient diagnosed with breast cancer less than 6 months ago
  • Patient under guardianship, curatorship or safeguard of justice

Treatment and study plan

Self-questionnaires and semi-structured interview

Behavioral

Patients will fill these questionnaires : BISF-W, QLQ-C30, QLQ-BR23 and if they agree answer to a semi-structured interview composed of 5 questions

Primary outcomes

  1. Assessment of sexual quality of life in women with HR+/HER2- metastatic breast cancer in first-line treatment

    Time frame: Day 0

    Patients will fill the questionnaire : BISF-W (Brief Index of Sexual Function for Women)

Secondary outcomes

  1. Assessment of overall quality of life in women with HR+/HER2- metastatic breast cancer in first-line treatment

    Time frame: Day 0

    Patients will fill the QLQ-C30 questionnaire

  2. Assessment of overall quality of life in women with HR+/HER2- metastatic breast cancer in first-line treatment

    Time frame: Day 0

    Patients will fill the QLQ+BR23 questionnaire

  3. Assessment of sexual and emotional intimacy

    Time frame: Day 0

    semi-structured interview composed of 5 questions

Sponsors and collaborators

Lead sponsor

Institut de Cancérologie de Lorraine

Other

Registry information

Official study title

Sexual Quality of Life and Metastatic Breast Cancer

Acronym: SexoMBC2

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Oct 13, 2022
Registry last updated
Jul 28, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.